Jason Aldred

Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease

Danna Jennings, Sarah Huntwork‐Rodriguez, Anastasia G. Henry et al. · Science Translational Medicine · 2022 · 230 citations

National randomized controlled trial of virtual house calls for Parkinson disease

Christopher A. Beck, Denise B. Beran, Kevin Biglan et al. · Neurology · 2017 · 215 citations · Full text

Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054

Laura Fanning, Serena Hung, Aaron Ellenbogen et al. · Movement Disorders · 2019 · 187 citations · Full text

Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial

Michael J. Soileau, Jason Aldred, Kumar Budur et al. · The Lancet Neurology · 2022 · 172 citations

Advanced Parkinson, Parkinson Disease, Neurology +3

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

Jason Aldred, Eric Freire-Álvarez, Angelo Antonini et al. · Neurology and Therapy · 2023 · 91 citations · Full text